Acute testosterone administration

Details Acute testosterone administration Acute testosterone administration

2000-05-02

2002-08-06

Dees, Jose′ G. (Department: 1619)

Drug, bio-affecting and body treating compositions

Effervescent or pressurized fluid containing

C424S046000, C424S434000, C514S253030, C552S638000

Reexamination Certificate

active

06428769

ABSTRACT:

FIELD OF THE INVENTION
This invention relates generally to a method of treating women with a decreased libido. More specifically, the invention relates to acute non-invasive administration of testosterone to enhance libido over a discrete period of time.
BACKGROUND OF THE INVENTION
The presence of a normal amount of libido, defined as the urge to engage in sexual activity, is an important component of an individual's well-being. In both men and women the primary naturally occurring hormone responsible for libido is testosterone. In males, the baseline testosterone level is a relatively constant throughout life, decreasing slowly in old age. In contrast, women elaborate testosterone only as part of the process of ovulation. Each maturing follicle produces testosterone at the mid-point of the menstrual cycle, consistent with observations that female libido peaks with ovulation. As a woman ages, the number of maturing follicles per month decreases, and there is a decreasing total amount of testosterone produced.
A common complaint of post menopausal women is decreased libido. This decrease in libido is characterized by a lack of interest in sexual intercourse, the lack of ability to achieve orgasm, or decrease in intensity of orgasm. It is important to note that this decrease in libido is often associated with a profound sense of loss of a once normal and active interest in sexual activity.
Clinicians frequently confronted with the problem of managing female patients presenting with decreased libido have limited tools to address the problem. Testosterone is available as an oral preparation and can be given, for instance, in combination with estrogen to restore testosterone levels. However, the replacement of the once pulsatile endogenous delivery of testosterone with the sustained blood level of the hormone produces unwanted side effects. Women taking testosterone for a few weeks typically begin to complain of the emergence of secondary sexual characteristics such as unwanted body hair, oily hair, and, with prolonged a use, deepening voice. For this reason, oral testosterone replacement therapy is not a practical solution for most patients with decreased libido.
Other forms of testosterone replacement therapy for women are being explored. A transdermal patch capable of delivering a steady rate of testosterone is being tested for use in women. As with oral testosterone replacement therapy, the study state blood levels of testosterone produced via transdermal delivery are likely to be associated with the same side effect profile issues.
It is recognized that testosterone in females decreases with age (Human Biology, May 1980, volume of 52, No. 2, pages 181-0191.). It is also known that sexual motivation in post menopausal women is associated with the levels of exogenously introduced testosterone (Psychosomatic Medicine volume 47, No. 4, 1985). Further, providing intravenous testosterone to women as part of clinical studies is known (American Journal of Obstetrics and Gynecology, December 1986 pages 1288 to 1292).
SUMMARY OF THE INVENTION
A method of increasing the libido of a woman over a discrete period of time (e.g. 30-240 minutes) by the administration of testosterone is disclosed. A formulation comprised of testosterone is aerosolized preferably producing particles which have a size in a range of from about 1 to 3 microns which can be inhaled into areas of the lung where they can readily enter the blood stream. The aerosol is inhaled into the lungs of a patient. Once inhaled, particles of testosterone deposits on lung tissue and from there enter the patient's circulatory system and thereby increase the patient's serum testosterone level. The percentage increase in the patient's testosterone level will vary depending on the needs of the patient. However, the patient's normal baseline serum testosterone level is preferably increased 25% or more and more preferably 100% or more. Because delivery is by inhalation the patient's serum testosterone level is quickly raised to a desired level e.g. in thirty minutes or less, more preferably fifteen minutes or less. When the patient's testosterone level is raised to a desired level the patient's libido is increased. The increased testosterone level gradually subsides (as the testosterone is metabolized and cleared) thereby avoiding the adverse side effects generated by maintaining enhanced testosterone levels over long periods.
An aspect of the invention is a method of treatment whereby testosterone or derivative thereof is aerosolized, inhaled and provided to the circulatory system of the patient at levels sufficient to increase libido (over a short period of time) and propensity for orgasm.
An advantage of the invention is that the testosterone levels are raised within minutes of administration and return to normal levels within hours—preferably in less than four hours.
Another advantage is that the administered testosterone is quickly metabolized allowing the patient's testosterone levels to return to normal thereby avoiding the adverse effects of long term administration.
A feature of the invention is that aerosolized particles of testosterone having a diameter of about 0.5 to 8 microns (preferably 1-3 microns) are created and inhaled deeply into the lungs thereby enhancing the speed and efficiency of administration.
It is an object of this invention to describe the utility of delivering testosterone or dihydrotestosterone by inhalation as a means of treating women with decreased libido and/or decreased propensity to have orgasms.
It is another object of this invention to describe liquid formulations (which includes suspensions) of testosterone and derivatives thereof such as dihydrotestosterone appropriate for pulmonary delivery.
It is another object of this invention to describe how testosterone or dihydrotestosterone delivered via the lung can quickly increase plasma levels substantially beyond baseline levels for the patient.
It is another object of this invention to describe the blood levels of testosterone or dihydrotestosterone required for rapid onset of a normal to enhanced libido in women with baseline decreased libido.
It is another object of this invention to describe the time course of inhalation of testosterone or dihydrotestosterone and the onset of increased libido in women suffering from decreased libido.
It is another object of this invention to describe how the pulsatile delivery of testosterone or dihydrotestosterone as replacement therapy for women with decreased libido is associated with a decreased incidence of side effects (secondary sexual characteristics) commonly associated with traditional testosterone replacement therapy which produces a steady state level of the hormone.
The delivery of testosterone by inhalation provides, for the first time, the means for non-invasively delivering clinically relevant amounts of testosterone on demand near the time of planned intercourse.
It is an object of the invention to provide a method of treatment of erectile dysfunction in a patient comprising the steps of aerosolizing a formulation comprising sildenafil citrate, inhaling the aerosolized formulation into the lungs of a patient, and allowing the particles of sildenafil citrate to deposit on lung tissue and enter the patient's circulatory system.
It is an object of the invention to provide an aerosolized formulation comprised of sildenafil citrate and a carrier, the aerosol being characterized by particles having a diameter in the range of about 1.0 micron to 5.0 microns making up 50% or more of the aerosol particles.
It is an object of the invention to provide a kit comprising an aerosol delivery device and a formulation comprising a testosterone, sildenafil citrate, or a combination thereof.
It is an object of the invention to provide a kit comprising two aerosol delivery devices and two formulations, a first formulation comprising a testosterone for use by a women, and a second formulation comprising a testosterone, sildenafil citrate, or a combination thereof, fo

Affiliated with

Also associated with

Rating

Acute testosterone administration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acute testosterone administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acute testosterone administration will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2945119